HK Stock Market Move | AKESO (09926) rose more than 3% in the early trading session. The updated data on the first-line treatment of TNBC by Ivo West in ESMO IO 2025 will be released.

AKESO (09926) rose more than 3% in early trading, rising 2.83% as of the time of writing to 120.2 Hong Kong dollars, with a trading volume of 100 million Hong Kong dollars. On the news front, on December 11, according to the official Weibo account of AKESO, at the ESMO IO 2025 European Immuno-Oncology Congress held recently in London, AKESO announced updated and released excellent efficacy data from a longer follow-up period of a Phase II clinical study of the company's independently developed PD-1/VEGF bispecific antibody, Ivosidenib, in combination with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), demonstrating the huge clinical potential of the Ivosidenib regimen in the first-line treatment of TNBC. Previously, based on excellent efficacy and safety, Ivosidenib in combination therapy for the first-line treatment of TNBC has been included in the breakthrough therapy drug (BTD) list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. Currently, a multicenter, randomized, double-blind Phase III clinical trial (HARMONi-BC1/AK112-308) for Ivosidenib in this indication is progressing efficiently. It is reported that Ivosidenib monoclonal antibody is a globally pioneering PD-1/VEGF bispecific tumor immunotherapy drug independently developed by AKESO. The first indication for Ivosidenib was approved for marketing by the Chinese National Medical Products Administration in May 2024 for the treatment of locally advanced or metastatic nsq-NSCLC progressing after EGFR-TKI treatment. Ivosidenib has become the world's first bispecific antibody new drug with a "tumor immunotherapy + anti-angiogenesis" synergistic anti-tumor mechanism to be approved for marketing. In November of the same year, Ivosidenib monoclonal antibody was included in the national medical insurance directory.